Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2017 1
2018 2
2019 3
2020 3
2021 3
2022 3
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Early Prediction of Response Focused on Tumor Markers in Atezolizumab plus Bevacizumab Therapy for Hepatocellular Carcinoma.
Tanabe N, Saeki I, Aibe Y, Matsuda T, Hanazono T, Nishi M, Hidaka I, Kuwashiro S, Shiratsuki S, Matsuura K, Egusa M, Nishiyama N, Fujioka T, Kawamoto D, Sasaki R, Nishimura T, Oono T, Hisanaga T, Matsumoto T, Ishikawa T, Yamasaki T, Takami T. Tanabe N, et al. Among authors: nishimura t. Cancers (Basel). 2023 May 26;15(11):2927. doi: 10.3390/cancers15112927. Cancers (Basel). 2023. PMID: 37296889 Free PMC article.
Methylated SEPT9 assay-based liquid biopsy as a biomarker in molecular targeted agent-treated hepatocellular carcinoma.
Saeki I, Suehiro Y, Yamauchi Y, Hoshida T, Tanabe N, Oono T, Kawamoto D, Nishimura T, Matsumoto T, Ishikawa T, Shimokawa M, Tamori A, Kawada N, Tamai Y, Iwasa M, Nakagawa H, Nagano H, Takami T, Yamasaki T. Saeki I, et al. Among authors: nishimura t. Hepatol Int. 2023 Oct;17(5):1289-1299. doi: 10.1007/s12072-023-10488-y. Epub 2023 Apr 25. Hepatol Int. 2023. PMID: 37186217
A combination of liver stiffness and international normalized ratio is an ideal prognostic predictor of portosystemic shunt occlusion in patients with portal hypertension.
Ishikawa T, Egusa M, Fujioka T, Nishiyama N, Kawamoto D, Sasaki R, Nishimura T, Tanabe N, Oono T, Saeki I, Takami T. Ishikawa T, et al. Among authors: nishimura t. J Gastroenterol. 2023 Mar;58(3):246-256. doi: 10.1007/s00535-022-01947-8. Epub 2022 Dec 30. J Gastroenterol. 2023. PMID: 36583759
Double cancer of primary hepatic angiosarcoma and hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Yamauchi Y, Saeki I, Yamasaki T, Egusa M, Nishiyama N, Fujioka T, Kawamoto D, Nishimura T, Tanabe N, Oono T, Matsumoto T, Ishikawa T, Marumoto Y, Matsukuma S, Shindo Y, Tokumitsu Y, Yoshimine S, Murakami J, Tanaka T, Kimura S, Hoshii Y, Hamano K, Nagano H, Takami T. Yamauchi Y, et al. Among authors: nishimura t. Hepatol Res. 2023 Jul;53(7):681-686. doi: 10.1111/hepr.13894. Epub 2023 Mar 14. Hepatol Res. 2023. PMID: 36826420
Short-term Effects of Hepatic Arterial Buffer Responses Induced by Partial Splenic Embolization on the Hepatic Function of Patients with Cirrhosis According to the Child-Pugh Classification.
Ishikawa T, Sasaki R, Nishimura T, Matsuda T, Iwamoto T, Saeki I, Hidaka I, Takami T, Sakaida I. Ishikawa T, et al. Among authors: nishimura t. Intern Med. 2021 May 1;60(9):1331-1342. doi: 10.2169/internalmedicine.6267-20. Epub 2020 Dec 7. Intern Med. 2021. PMID: 33281164 Free PMC article.
Splenic non-infarction volume determines a clinically significant hepatic venous pressure gradient response to partial splenic embolization in patients with cirrhosis and hypersplenism.
Ishikawa T, Sasaki R, Nishimura T, Matsuda T, Iwamoto T, Saeki I, Hidaka I, Takami T, Sakaida I. Ishikawa T, et al. Among authors: nishimura t. J Gastroenterol. 2021 Apr;56(4):382-394. doi: 10.1007/s00535-021-01762-7. Epub 2021 Feb 24. J Gastroenterol. 2021. PMID: 33629147
19 results